Author

E. Ivanova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Herrera· 3 shared A. Rashidfarrokhi· 2 shared A. Tsirigos· 2 shared C. M. Rudin· 2 shared K. M. Khanna· 2 shared K.-k. Wong· 2 shared R. Pillai· 2 shared S. B. Koralov· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Herrera

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

R. Pillai, S. E. LeBoeuf, Y. Hao, C. New, J. Blum, A. Rashidfarrokhi, S. M. Huang, C. Bahamon, W. L. Wu, B. Karadal-Ferrena, A. Herrera, E. Ivanova, M. Cross, J. P. Bossowski, H. Ding, , T. Papagiannakopoulos

This study shows that DRP-104, a glutamine antagonist, suppresses KEAP1 mutant lung tumor growth and enhances response to checkpoint blockade by inhibiting glutamine metabolism and improving T cell function.

bioRxiv · Jun 27, 2023 · PreprintCancer Biology

FOXA2 controls the anti-oxidant response in FH-deficient cells

C. Rogerson, M. Sciacovelli, L. A. Maddalena, L. Valcarcel-Jimenez, C. Schmidt, M. Yang, E. Ivanova, J. Kent, A. Mora, D. Cheeseman, J. S. Carroll, G. Kelsey, C. Frezza

This study identifies FOXA2 as a key transcription factor regulating the anti-oxidant response in FH-deficient cells, independent of NRF2, and highlights its role in metabolic rewiring.

bioRxiv · Jul 4, 2022Cancer Biology

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

A. M. Zavitsanou, Y. Hao, W. L. Wu, E. Bartnicki, R. Pillai, T. Karakousi, A. Herrera, A. Karatza, A. Rashidfarrokhi, S. Solis, M. Ciampricotti, A. H. Yeaton, E. Ivanova, C. A. Wohlhieter, T. B. Buus, , S. B. Koralov

This study shows KEAP1 mutations in lung adenocarcinoma lead to immune evasion by reducing dendritic cell and T cell responses, contributing to immunotherapy resistance.

bioRxiv · Sep 24, 2021 · PreprintCancer Biology

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19

M. de Vries, A. Mohamed, R. A. Prescott, A. Valero-Jimenez, L. Desvignes, R. O'Connor, C. Steppan, J. C. Devlin, E. Ivanova, A. Herrera, A. Schinlever, P. Loose, K. Ruggles, S. Koralov, A. Anderson, , M. Dittmann

This study compares the antiviral efficacy of PF-00835231, GC-376, and remdesivir in human airway models, showing PF-00835231 is at least as potent as the others and not affected by P-glycoprotein efflux.

bioRxiv · Aug 28, 2020 · PreprintMicrobiology

Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy

S. A. Mills, A. Jobling, M. A. Dixon, B. V. Bui, K. A. Vessey, J. A. Phipps, U. Greferath, G. Venables, V. H. Y. Wong, C. H. Y. Wong, Z. He, F. Hui, J. C. Young, J. Tonc, E. Ivanova, , E. L. Fletcher

This study shows microglia regulate retinal capillary constriction via fractalkine-Cx3cr1 signaling and RAS pathway, with dysfunction occurring early in diabetic retinopathy.

bioRxiv · Jun 15, 2020Cell Biology